COMMUNIQUÉS West-GlobeNewswire

Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
09/05/2024
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches based on [...]
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
08/05/2024
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta [...]
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
08/05/2024
Company acquired all assets for the synergistic CNSide cerebrospinal fluid diagnostic portfolio Company will summarize topline data from the FORESEE clinical trial planned for presentation at the SNO/ASCO Meeting in [...]
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
08/05/2024
NEW YORK and WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement [...]
Travere Therapeutics to Present at Upcoming Investor Conferences
08/05/2024
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities Health Care [...]
STERIS Announces Financial Results for Fiscal 2024 Fourth Quarter and Full Year
08/05/2024
Total fiscal 2024 revenue increased 12% to $5.5 billion Total fiscal 2024 U.S. GAAP earnings per diluted share of $3.81; adjusted earnings per diluted share increased to $8.83 Targeted restructuring plan announced [...]
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
08/05/2024
SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024 Clinical study reports for the FURI, CARES and NATURE trials in refractory invasive fungal [...]
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
08/05/2024
Conference Call to Begin Today at 5:00 p.m. (ET) 1Q 2024 Total revenues of $66M; +63% vs. 1Q 2023 1Q 2024 Net income of $11M; Non-GAAP net income of $15M $304M of cash and cash equivalents and investments at March 31, [...]
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
08/05/2024
Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of $66.8 Million, a 16.2% [...]
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
08/05/2024
Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024 ASCO Annual Meeting; preparing for a potential phase 3 trial Zeno BLA accepted for priority review by the FDA for the [...]
Dentsply Sirona to Participate in Upcoming Investor Conferences
08/05/2024
CHARLOTTE, N.C., May 08, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced its participation at upcoming conferences. Bank of America 2024 Health Care [...]
Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference
08/05/2024
ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space [...]
Precision Optics Corporation Schedules Third Quarter of Fiscal Year 2024 Conference Call for Wednesday, May 15, 2024
08/05/2024
GARDNER, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense [...]
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
08/05/2024
- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting [...]
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
08/05/2024
- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial signs of efficacy [...]
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
08/05/2024
- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW, Calif., May 08, 2024 [...]
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
08/05/2024
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, currently enrolling End-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis [...]
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
08/05/2024
Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF trial in Dry Eye [...]
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
08/05/2024
ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 [...]

Pages